Information Provided By: 
Fly News Breaks for November 6, 2019
TBPH
Nov 6, 2019 | 05:21 EDT
Piper Jaffray analyst Tyler Van Buren lowered his price target for Theravance Biopharma to $40 from $55 after pushing back the launch timing TD-1473 post the company's Q3 results. The analyst, however, says Trelegy continued its steady quarter-over-quarter growth despite seasonality. The launch could further inflect with an approval in asthma mid next year, Van Buren tells investors in a research note. He keeps an Overweight rating on Theravance Biopharma.
News For TBPH From the Last 2 Days
There are no results for your query TBPH
